Cullinan Common Stock Total Equity from 2010 to 2024
| CGEM Stock | USD 17.44 0.35 2.05% |
Common Stock Total Equity | First Reported 2010-12-31 | Previous Quarter 5.8 K | Current Value 6 K | Quarterly Volatility 2 K |
Check Cullinan Oncology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cullinan Oncology's main balance sheet or income statement drivers, such as Interest Expense of 679 M, Selling General Administrative of 44.6 M or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 28.86, Dividend Yield of 0.0 or PTB Ratio of 0.98. Cullinan financial statements analysis is a perfect complement when working with Cullinan Oncology Valuation or Volatility modules.
Cullinan | Common Stock Total Equity |
Latest Cullinan Oncology's Common Stock Total Equity Growth Pattern
Below is the plot of the Common Stock Total Equity of Cullinan Oncology LLC over the last few years. It is the total value of common stock equity held by shareholders, representing their ownership interest in the company. Cullinan Oncology's Common Stock Total Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cullinan Oncology's overall financial position and show how it may be relating to other accounts over time.
| Common Stock Total Equity | 10 Years Trend |
|
Common Stock Total Equity |
| Timeline |
Cullinan Common Stock Total Equity Regression Statistics
| Arithmetic Mean | 2,119 | |
| Geometric Mean | 1,547 | |
| Coefficient Of Variation | 92.81 | |
| Mean Deviation | 1,641 | |
| Median | 1,000.00 | |
| Standard Deviation | 1,967 | |
| Sample Variance | 3.9M | |
| Range | 5K | |
| R-Value | 0.78 | |
| Mean Square Error | 1.6M | |
| R-Squared | 0.60 | |
| Significance | 0.0006 | |
| Slope | 342.01 | |
| Total Sum of Squares | 54.2M |
Cullinan Common Stock Total Equity History
About Cullinan Oncology Financial Statements
Cullinan Oncology investors utilize fundamental indicators, such as Common Stock Total Equity, to predict how Cullinan Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Common Stock Total Equity | 5.8 K | 6 K |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Cullinan Oncology LLC using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Additional Information and Resources on Investing in Cullinan Stock
When determining whether Cullinan Oncology LLC is a strong investment it is important to analyze Cullinan Oncology's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cullinan Oncology's future performance. For an informed investment choice regarding Cullinan Stock, refer to the following important reports:Check out the analysis of Cullinan Oncology Correlation against competitors. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cullinan Oncology. If investors know Cullinan will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cullinan Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.13) | Return On Assets (0.22) | Return On Equity (0.29) |
The market value of Cullinan Oncology LLC is measured differently than its book value, which is the value of Cullinan that is recorded on the company's balance sheet. Investors also form their own opinion of Cullinan Oncology's value that differs from its market value or its book value, called intrinsic value, which is Cullinan Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cullinan Oncology's market value can be influenced by many factors that don't directly affect Cullinan Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cullinan Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cullinan Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cullinan Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.